ANNX VS VAXX Stock Comparison

Performance

ANNX
10/100

ANNX returned -58.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

VAXX
10/100

VAXX returned -26.82% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

ANNX
72/100

ANNX had a bullish sentiment score of 71.85% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.07 likes per day.

VAXX
71/100

VAXX had a bullish sentiment score of 70.79% across Twitter and StockTwits over the last 12 months. It had an average of 2.38 posts, 1.25 comments, and 1.62 likes per day.

Technicals

ANNX
64/100

ANNX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

VAXX
64/100

VAXX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

ANNX
10/100

ANNX has missed earnings 7 times in the last 20 quarters.

VAXX
100/100

VAXX has missed earnings 1 times in the last 20 quarters.

Profit

ANNX
10/100

Out of the last 19 quarters, ANNX has had 0 profitable quarters and has increased their profits year over year on 1 of them.

VAXX
10/100

Out of the last 14 quarters, VAXX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ANNX
49/100

ANNX has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

VAXX
60/100

VAXX has had a higher than average amount of volatility over the last 12 months giving it a score of 59 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Annexon, Inc. Common Stock Summary

Nasdaq / ANNX

Healthcare

Biotechnology

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Vaxxinity, Inc. Class A Common Stock Summary

Nasdaq / VAXX

Healthcare

Biotechnology

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Power up your portfolio